Background. The pathogenic mechanisms involved in Helicobacter pylori-induced duodenal mucosal injury are incompletely understood. In the present study, we sought to investigate the effect of H. pylori vacuolating cytotoxin (VacA) on duodenal mucosal bicarbonate (HCO 3 Ϫ ) secretion. Methods. Concentrated bacterial culture supernatants from an H. pylori wild-type strain producing VacA with s1/m1 genotypes (P12) and from an isogenic mutant lacking VacA (P12⌬vacA) were used. HCO 3 Ϫ secretion by murine duodenal mucosa was examined in vitro in Ussing chambers. Duodenal mucosal histamine release was measured using enzyme-linked immunosorbent assay. The expression of histamine H 2 receptor was examined by immunohistochemical analysis.
Helicobacter pylori infection occurs worldwide, and it is now widely accepted as a major cause of duodenal ulcer formation [1, 2] . However, the pathogenesis of H. pyloriinduced duodenal ulcers is not fully understood.
H. pylori infects a majority of the human population, with a very high prevalence noted in countries with poor hygienic conditions. However, only a minority of persons infected with H. pylori developed gastroduodenal diseases. Pathogenesis depends on strain virulence, host genetic susceptibility, and environmental cofactors [3] . The vacuolating cytotoxin (VacA) gene is present in most H. pylori strains, and ϳ50% of H. pylori strains secrete VacA [4] . The studies have shown that VacA, especially VacA with s1/m1 genotypes, is closely associated with peptic ulceration [3] [4] [5] .
Duodenal mucosal bicarbonate (HCO 3 Ϫ ) secretion plays an important role in duodenal mucosal protection against acid-peptic injury [6 -9] . Patients with duodenal ulcer have significantly diminished proximal duodenal mucosal HCO 3 Ϫ secretion, compared with healthy volunteers [10] , suggesting that diminished mucosal HCO 3 Ϫ secretion contributes to the pathogenesis of duodenal ulcer. In patients with duodenal ulcer associated with H. pylori, duodenal HCO 3 Ϫ secretion was diminished, and, after eradication of H. pylori, it returned to normal levels [11] . This finding indicated that H. pylori infection impaired the capacity of duodenal mucosal HCO 3 Ϫ secretion. In a previous study, Debellis et al. [12] found that H. pylori cytotoxin VacA stimulated HCO 3 Ϫ efflux in an isolated frog stomach model. On the other hand, intraluminal perfusion of H. pylori water extract was shown to inhibit acid-induced duodenal mucosal HCO 3 Ϫ secretion in rats in vivo [13] . H. pylori water extract strongly decreased murine duodenal HCO 3 Ϫ secretion in vitro within 1 h of incubation [14] . These results indicate that products secreted by H. pylori likely influence duodenal mucosal HCO 3 Ϫ secretion.
However, H. pylori water extract is a crude mixture that contains many unidentified components, and the nature of these products and the underlying mechanism(s) involved remain unclear.
In the present study, therefore, we investigated both the effect of H. pylori VacA on duodenal mucosal HCO 3 Ϫ secretion and the underlying mechanisms for the VacA-induced reduction in HCO 3 Ϫ secretion, by use of concentrated culture supernatants from isogenic H. pylori strains producing VacA with S1/m1 genotypes and from isogenic mutation strains lacking VacA. In selected experiments, we also studied the effect of highly purified VacA toxin. We sought to illustrate the pathogenesis of H. pylori-induced duodenal ulcer. The results demonstrated that VacA inhibits prostaglandin E 2 (PGE 2 )-stimulated duodenal mucosal HCO 3 Ϫ secretion in a histamine-dependent manner.
MATERIAL AND METHODS

Materials.
The reagents, PGE 2 , cimetidine, ranitidine, diphenhydramine, thioperamide, and histamine, were purchased from Sigma. These reagents were dissolved in dimethyl sulfoxide (DMSO) or water for stock. Rabbit anti-histamine H 2 receptor affinity-purified polyclonal antibody and nonimmune mouse IgG used as negative control were obtained from Chemicon International. All other chemicals in solutions were obtained from Sigma and Calbiochem. Preparation and purification of H. pylori VacA. The concentrated culture supernatants from an H. pylori wild-type strain producing VacA with s1/m1 genotypes (P12) and its isogenic mutant with a deletion of the VacA gene (P12⌬vacA) were prepared as described elsewhere [15] . In brief, H. pylori strain 60190 was cultured in Brucella broth supplemented with 10% fetal calf serum. The broth cultures were incubated for 2 days with mild agitation. The bacteria were pelleted by centrifugation, and the supernatant was passed through a 0.2-m pore sterile filter. Proteins of the culture supernatant were precipitated with a 50% saturated solution of ammonium sulfate. The precipitate was resolved in PBS and underwent dialysis against PBS overnight. The protein concentration was determined using Bradford reagent. The H. pylori P12 vacA deletion mutant strain was constructed by polymerase chain reaction (PCR) amplification and cloning into pBluescript II SK of the upstream and downstream regions of vacA and by insertion of a cat resistance gene cassette. The correctly verified plasmid (pWS59) was used for transformation of H. pylori P12 to generate a nonpolar mutant. VacA was purified from culture supernatant by precipitation with a 44% saturated solution of ammonium sulfate and by gel filtration chromatography performed with the use of a Sephacryl S300 16/60 column (Pharmacia Biotech). Fractions were tested for VacA by Western blot analysis and were concentrated using Amicon Ultra 100K centrifugal filter devices. The purified toxin was assayed for functional activity in a vacuolization assay.
Animal preparation. All studies were approved by the committees on investigations involving animals at Hannover Medical School (Hannover, Germany) and Zunyi Medical College (Zunyi, China). Experiments were performed in NMRI mice (age, 6 -12 weeks). The mice were housed in a standard animal care room with a light-dark cycle of 12:12 h, and they were allowed free access to food and water. After narcosis was briefly induced with 100% CO 2 , the mice were killed by cervical dislocation. The abdomen of each mouse was opened by making a midline incision, and the proximal duodenum (the portion stretching approximately from 2 mm distal to the pylorus to the common bile duct ampulla) was removed and immediately placed in ice-cold iso-osmolar mannitol and indomethacin (1 mol/L) solution (to suppress trauma-induced prostaglandin release). The duodenum was opened along the mesenteric border and was stripped of external serosal and muscle layers by sharp dissection in the aforementioned ice-cold iso-osmolar mannitol and indomethacin solution.
Ussing chamber experiments for the measurement of HCO 3 ؊ secretion. Ussing chamber experiments were performed as described elsewhere [16, 17] . In brief, the duodenal mucosae were mounted between the 2 chambers with an exposed area of 0.196 cm 2 Measurement of histamine release. The mice were prepared as described above. Segments of proximal duodenal tissue (ϳ50 mg), opened along the mesenteric border and stripped of seromuscular layers, were placed in serosal Ringer's solution gassed with 95% O 2 and 5% CO 2 at 37°C, to incubate for different time points in the presence of 40 g/mL P12 supernatant or to incubate for 45 min in the presence of various P12 supernatant concentrations. At the end of the incubation period, the incubation media were centrifuged, and the supernatants were stored at Ϫ70°C for later histamine assay. The tissues were homogenized at 4°C in perchloric acid (66%; 10 L/mg tissue) for the extraction of histamine. The resulting suspension was centrifuged (at 425 g at 4°C for 10 min) to remove solid matter and precipitated protein, and the fluid phase was transferred to a clean tube and neutralized with the addition of an equal volume of potassium borate (1 mol/L; pH 9.25; ϳ500 l). The samples were then recentrifuged, and the supernatants were stored at Ϫ70°C for histamine assay. Measurement of histamine was performed using ELISA, with the use of a histamine ELISA kit (SPI-BIO) according to the manufacturer's guidelines. Release of histamine in the incubation medium was expressed as a percentage of the total histamine content in tissue.
Immunohistochemical analysis. For immunohistochemical determination of histamine H 2 receptor expression, proximal duodenal tissue specimen was fixed in 10% buffered formalin solution, dehydrated, and then embedded in paraffin. The preparation was cut in 5-m sections, deparaffinized, and treated for 10 min with citrate buffer (10 mmol/L citric acid; pH 6.0) in a microwave oven (750 W) before immunostaining was done. Endogenous peroxidase activity was quenched by incubation in 3% hydrogen peroxide for 7 min. After incubation with rabbit anti-histamine H 2 receptor affinity-purified polyclonal antibody (Chemicon) overnight at 4°C, the sections were washed with PBS and exposed to Dako EnVision Detection Systems Peroxidase/DAB, Rabbit/Mouse (Dako) for 30 min at room temperature. Slides were rinsed in PBS, incubated with the Dako Liquid DAB Large-Volume Substrate-Chromogen System (Dako), rinsed gently with distilled water, and counterstained with hematoxylin. Coverslips were mounted using mounting mediums and were examined using a Leica microscope. The specificity of immunoreactivity was confirmed by negative controls in which nonimmune mouse IgG was used instead of the primary antibodies.
Statistics. All results are expressed as the mean Ϯ SE. "⌬HCO 3 Ϫ " denotes the stimulated peak responses minus the basal values (i.e., the net stimulated murine HCO 3 Ϫ secretion).
Basal values for HCO 3 Ϫ secretion denote the average value determined for the 20-min period before the administration of PGE 2 . Data were analyzed by 1-way analysis of variance (ANOVA), followed by Newman-Keuls post hoc test or, when appropriate, by Student's t tests. P Ͻ .05 was considered to denote statistical significance. Ϫ secretion). Control vehicle, either 40 g/mL P12 or 40 g/mL P12⌬vacA was added to the mucosal side of tissues 60 min before stimulation with PGE 2 (10 Ϫ6 mol/L). Results are expressed as the mean Ϯ SE, and, for each series, n ϭ 10. P12 markedly reduced PGE 2 -stimulated HCO 3 Ϫ secretion, whereas P12⌬vacA had no significant effect on PGE 2 -stimulated HCO 3 Ϫ secretion. (*P Ͻ .0001 and **P Ͼ .05, compared with control; †P Ͻ .001, compared with P12⌬vacA, by 1-way analysis of variance with Student's t test or Newman-Keuls post hoc test).
RESULTS
Effect of
course figure not shown) during incubation for 2 h. The basal HCO 3 Ϫ secretions determined before the addition of P12 and P12⌬vacA were, respectively, 1.14 Ϯ 0.08 and 1.21 Ϯ 0.11 mol/cm 2 /h (n ϭ 8). After incubation for 1 h, HCO 3 Ϫ secretions in the presence of P12 or P12⌬vacA were, respectively, 1.23 Ϯ 0.12 and 1.27 Ϯ 0.14 mol/ cm 2 /h (P Ͼ .05, compared with values obtained before the addition of P12 and P12⌬vacA). Thus, neither P12 nor P12⌬vacA altered basal HCO 3 Ϫ secretion.
To assess tissue viability, 25 mmol/L luminal glucose was added at the end of the experiment. Glucose increased shortcircuited current to a similar degree in P12-exposed tissue and control tissue, indicating that the viability of tissue was not influenced by P12 and P12⌬vacA (data not shown).
VacA inhibits PGE 2 -stimulated duodenal mucosal HCO 3 ؊ secretion. PGE 2 is believed to play an important role in the regulation of duodenal mucosal HCO 3 Ϫ secretion. Therefore, we investigated the effect of VacA on PGE 2 -stimulated duodenal HCO 3 Ϫ secretion. After mucosae were incubated for 1 h with 40 g/mL P12 or 40 g/mL P12⌬vacA, P12 markedly reduced PGE 2 -stimulated duodenal mucosal HCO 3 Ϫ secretion by 49%
(P Ͻ .0001), whereas P12⌬vacA only slightly, but not significantly, reduced PGE 2 -stimulated HCO 3 Ϫ secretion by 17%
(P Ͼ .05) ( figure 1A and 1B) . Furthermore, the inhibitory action of P12 on PGE 2 -stimulated HCO 3 Ϫ secretion was dose dependent over a range of concentrations from 5 to 100 g/mL (figure 2). P12⌬vacA did not significantly reduce PGE 2 -stimulated HCO 3 Ϫ secretion, even at a concentration of 100 g/mL (data not shown). We then performed experiments with purified VacA. Purified VacA, 1 g/ml, which had exerted its functional activity at this concentration [15] , produced comparable inhibition of PGE 2 -stimulated HCO 3 Ϫ secretion, reducing it by 51% (P Ͻ .001) ( figure 3 VacA stimulates duodenal histamine release. Next, we examined the effect of VacA on histamine release from the duodenal mucosa. Histamine released from tissues after incubation with P12 was expressed as a percentage of the total tissue con- Ϫ ] secretion). Experiments were conducted as described in the figure 1 legend, except that various doses of only P12 were added. Each dose was tested independently in a separate tissue. Results are expressed as the mean Ϯ SE, and, for each series, n у 8. P12 inhibited PGE 2 -stimulated HCO 3 Ϫ secretion in a dosedependent manner. (*P Ͼ .05, **P Ͻ .01, and †P Ͻ .0001, compared with control, by 1-way analysis of variance with Student's t test and Newman-Keuls post hoc test).
tent. As shown in figure 5, after incubation with 40 g/mL P12 for 15 min, duodenal mucosal histamine release was markedly increased (P Ͻ .05), and it reached maximal levels at 45 min (P Ͻ .001) (figure 5A), whereas P12⌬vacA had no significant effect on duodenal mucosal histamine release after incubation for 45 min (P Ͼ .05) (figure 5B). The effect of P12 on duodenal mucosal histamine release was dose dependent over a range of concentrations from 5 to 100 g/mL ( figure 5C ). These results demonstrated that VacA stimulates duodenal mucosal histamine release. secretion. We further examined the location of histamine H 2 receptor within the duodenal mucosa by using an immunohistochemical method. Figure 7 shows that histamine H 2 receptor was expressed on duodenal epithelial cells, the enteric nerve plexus, and lymphocytes in Peyer's patch, indicating that histamine H 2 receptors are widely expressed on the duodenal mucosa of the mouse.
DISCUSSION
Clinical studies have shown that patients with duodenal ulcer disease have markedly diminished basal and stimulated duodenal mucosal HCO 3 Ϫ secretion [10, 19] , suggesting that a relative lack of duodenal HCO 3 Ϫ secretion may be a factor in the pathogenesis of duodenal ulcer. In the present study, we found that a VacA-positive H. pylori supernatant and purified VacA markedly reduced PGE 2 -stimulated duodenal HCO 3 Ϫ secretion, whereas the supernatant of an isogenic VacA-negative mutant did not. Because the 2 supernatants from the isogenic strains differed only in the presence or absence of the VacA gene product, these results indicated that H. pylori VacA inhibits PGE 2 -stimulated duodenal mucosal HCO 3 Ϫ secretion. The effect of
VacA on PGE 2 -stimulated duodenal HCO 3 Ϫ secretion was dose dependent. In an attempt to understand the mechanism for VacA-mediated inhibition of duodenal HCO 3 Ϫ secretion, we measured the mucosal release of histamine by incubating the duodenal mucosa with the H. pylori supernatant, and we found that, in a dose-dependent manner, the VacA-positive supernatant caused a mucosal release of histamine. The concomitant application of H 2 receptor antagonists, but not H 1 or H 3 -receptor antagonists, attenuated the inhibitory effect of VacA-positive supernatant, suggesting an inhibition of duodenal HCO 3 Ϫ secretion via a local release of histamine acting on H 2 receptors, the presence of which we could demonstrate on murine duodenal epithelial cells as well as on neural and lymphatic structures. The precise mechanism for H. pylori-induced duodenal ulcer is not fully understood. The present conceivable reasons for the development of duodenal ulcer in H. pylori-infected subjects include the possibility that H. pylori infection of the antrum induces hypersecretion of gastric acid, leading to an increased duodenal acid load and giving rise to gastric metaplasia in the duodenal bulb. The gastric metaplasia leads to H. pylori colonization in the bulb, giving rise to duodenitis and impairing duodenal epithelial function [20 -22] . In this series of events, the major determinant is the prevalence of the virulent H. pylori strains and their density in the bulb [21] [22] [23] [24] [25] [26] . A number of virulence factors have been identified. VacA, a highly immunogenic 95-kDa protein that induces massive vacuolization in epithelial cells in vitro, is believed to play an important role in peptic ulceration [3, 4] . In the present study, our results demonstrated that H. pylori VacA markedly reduced PGE 2 -stimulated duodenal HCO 3 Ϫ secretion in a dose-dependent manner; this finding may have important pathophysiologic relevance. Under physio- Results are expressed as the mean Ϯ SE, and, for each series, n у 7. Histamine reduced PGE 2 -stimulated HCO 3 Ϫ secretion in a dose-dependent manner (*P Ͼ .05, **P Ͻ .05, †P Ͻ .01, and ‡P Ͻ .0001, compared with control, by 1-way analysis of variance with Student's t test or Newman-Keuls post hoc test).
logic conditions, luminal acid is a critical stimulus of proximal duodenal mucosal HCO 3 Ϫ secretion [8, 27] . secretion are unclear. It is possible that histamine, acting through H 2 receptors, either directly or indirectly activates within the duodenal mucosa a subpopulation of nerves that contain an inhibitory messenger. In addition, it is also possible that H 2 receptors are located on nerve plexus in the submucosa, which could release an inhibitory messenger that, in turn, activates a neural response. In either case, once the neurotransmitter is released, it is proposed to act directly on the epithelium to inhibit PGE 2 -stimulated duodenal HCO 3 Ϫ secretion. However, the precise mechanism of histamine's action on PGE 2 -stimulated duodenal HCO 3 Ϫ secretion may be complex and will require further study.
In conclusion, H. pylori VacA inhibits PGE 2 -stimulated duodenal epithelial HCO 3 Ϫ secretion via stimulating the release of mucosal histamine, which in turn inhibits HCO 3 Ϫ secretion in an H 2 receptor-dependent mechanism. H. pylori VacAmediated duodenal histamine release and subsequent inhibition of duodenal HCO 3 Ϫ secretion might therefore be important pathogenic factors contributing to H. pylori-associated duodenal mucosal injury.
